If you wait for a top growth stock to come down to a P/E of 20 or less, you may end up waiting forever and missing out on the opportunity completely. For years, Eli Lilly has been generating solid ...

Eli Lilly (NYSE:LLY) recently announced its plans ... import tariffs on medications under the Trump administration. LLY stock has fared well so far this year, up around 20%. At its current levels ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Lilly could obtain approval for a weight loss pill that would unlock even more growth. Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically ...

Eli Lilly is buying a new drug and lowering prices ... It's as simple as that -- and good enough for a 2.6% stock price bump. Rich Smith has no position in any of the stocks mentioned.

Approval for orforglipron would not only generate a lot of bullishness for the healthcare stock, but would also provide Eli Lilly with yet another blockbuster drug, and potentially enable it to ...

Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 5,770.20 ...

Shares of Eli Lilly & Co. LLY slipped 2.01% to $911.06 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...